Indication
Moderate to severe plaque psoriasis
Moderate to severe plaque psoriasis is a chronic, immune-mediated inflammatory skin disorder characterized by dysregulated keratinocyte proliferation driven by pro-inflammatory cytokine pathways. Read more about Moderate to severe plaque psoriasis
173 drugs 36 manufacturers
Drugs that treat it
Common Moderate to severe plaque psoriasis therapies.
COSENTYX SENSOREADY (2 PENS) (secukinumab)
COSENTYX SENSOREADY PEN (secukinumab)
COSENTYX SYRINGE (secukinumab)
COSENTYX UNOREADY PEN (secukinumab)
CIMZIA (certolizumab pegol)
CIMZIA STARTER KIT (certolizumab pegol)
CIMZIA POWDER FOR RECONST (certolizumab pegol)
CIMZIA (2 PACK) (certolizumab pegol)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonModerate to severe plaque psoriasis is a chronic, immune-mediated inflammatory skin disorder characterized by dysregulated keratinocyte proliferation driven by pro-inflammatory cytokine pathways.
Clinically, it manifests in pediatric or adult populations as well-demarcated, erythematous or hyperpigmented plaques covered with coarse, silvery-white scales that frequently cause pruritus, pain, and bleeding.
The moderate-to-severe classification designates disease involving more than 3% to 10% of total body surface area, extensive disease activity reflected in elevated assessment scores, or localized lesions in high-impact areas such as the face, palms, soles, genitalia, or scalp that substantially impair physical function and quality of life.
- nih.gov
Moderate to severe plaque psoriasis is a chronic, immune-mediated inflammatory skin disorder characterized by dysregulated keratinocyte proliferation driven by pro-inflammatory cytokine pathways Clinically, it manifests in pediatric or adult populations as well-demarcated, erythematous or hyperpigmented plaques covered with coarse, silvery-white scales that frequently cause pruritus, pain, and bleeding
- nih.gov
Moderate to severe plaque psoriasis is a chronic, immune-mediated inflammatory skin disorder characterized by dysregulated keratinocyte proliferation driven by pro-inflammatory cytokine pathways The moderate-to-severe classification designates disease involving more than 3% to 10% of total body surface area, extensive disease activity reflected in elevated assessment scores, or localized lesions in high-impact areas such as the face, palms, soles, genitalia, or scalp that substantially impair ph...
- medlineplus.gov
Clinically, it manifests in pediatric or adult populations as well-demarcated, erythematous or hyperpigmented plaques covered with coarse, silvery-white scales that frequently cause pruritus, pain, and bleeding
- nih.gov
Clinically, it manifests in pediatric or adult populations as well-demarcated, erythematous or hyperpigmented plaques covered with coarse, silvery-white scales that frequently cause pruritus, pain, and bleeding The moderate-to-severe classification designates disease involving more than 3% to 10% of total body surface area, extensive disease activity reflected in elevated assessment scores, or localized lesions in high-impact areas such as the face, palms, soles, genitalia, or scalp that substan...
- psoriasis.org
The moderate-to-severe classification designates disease involving more than 3% to 10% of total body surface area, extensive disease activity reflected in elevated assessment scores, or localized lesions in high-impact areas such as the face, palms, soles, genitalia, or scalp that substantially impair physical function and quality of life
- nih.gov
The moderate-to-severe classification designates disease involving more than 3% to 10% of total body surface area, extensive disease activity reflected in elevated assessment scores, or localized lesions in high-impact areas such as the face, palms, soles, genitalia, or scalp that substantially impair physical function and quality of life
Personalize your experience
Follow Moderate to severe plaque psoriasis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.